Department of Medicine, Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
J Gastroenterol Hepatol. 2021 Sep;36(9):2416-2423. doi: 10.1111/jgh.15430. Epub 2021 Feb 18.
The primary aim was to validate the Pancreatitis Activity Scoring System (PASS) in a multicenter prospectively ascertained acute pancreatitis (AP) cohort. Second, we investigated the association of early PASS trajectories with disease severity and length of hospital stay (LOS).
Data were prospectively collected through the APPRENTICE consortium (2015-2018). AP severity was categorized based on revised Atlanta classification. Delta PASS (ΔPASS) was calculated by subtracting activity score from baseline value. PASS trajectories were compared between severity subsets. Subsequently, the cohort was subdivided into three LOS subgroups as short (S-LOS): 2-3 days; intermediate (I-LOS): 3-7 days; and long (L-LOS): ≥7 days. The generalized estimating equations model was implemented to compare PASS trajectories.
There were 434 subjects analyzed including 322 (74%) mild, 86 (20%) moderately severe, and 26 (6%) severe AP. Severe AP subjects had the highest activity levels and the slowest rate of decline in activity (P = 0.039). Focusing on mild AP, L-LOS subjects (34%) had 28 points per day slower decline; whereas, S-LOS group (13%) showed 34 points per day sharper decrease compared with I-LOS (53%; P < 0.001). We noticed an outlier subset with a median admission-PASS of 466 compared with 140 in the rest. Morphine equivalent dose constituted 80% of the total PASS in the outliers (median morphine equivalent dose score = 392), compared with only 25% in normal-range subjects (score = 33, P value < 0.001).
This study highlighted that PASS can quantify AP activity. Significant differences in PASS trajectories were found both in revised Atlanta classification severity and LOS groups, which can be harnessed in AP monitoring/management (ClincialTrials.gov number, NCT03075618).
本研究的主要目的是在多中心前瞻性急性胰腺炎(AP)队列中验证胰腺炎活动评分系统(PASS)。其次,我们研究了早期 PASS 轨迹与疾病严重程度和住院时间(LOS)的关系。
数据通过 APPRENTICE 联盟(2015-2018 年)前瞻性收集。AP 严重程度根据修订的亚特兰大分类进行分类。通过从基线值中减去活动评分来计算 PASS 的差值(Δ PASS)。比较严重程度亚组之间的 PASS 轨迹。随后,将队列分为 LOS 亚组:短 LOS(S-LOS):2-3 天;中 LOS(I-LOS):3-7 天;长 LOS(L-LOS):≥7 天。采用广义估计方程模型比较 PASS 轨迹。
共分析了 434 例患者,其中 322 例(74%)为轻度 AP,86 例(20%)为中度严重 AP,26 例(6%)为重度 AP。重度 AP 患者的活动水平最高,活动下降速度最慢(P=0.039)。在轻度 AP 中,L-LOS 组(34%)的 PASS 下降速度每天慢 28 分,而 S-LOS 组(13%)的 PASS 下降速度每天比 I-LOS 组(53%)快 34 分(P<0.001)。我们注意到一个异常值亚组,其入院时的 PASS 中位数为 466,而其余患者的中位数为 140。阿片类药物等效剂量占异常值患者 PASS 总分的 80%(中位数吗啡当量评分 392),而正常范围患者仅占 25%(评分 33,P 值<0.001)。
本研究表明,PASS 可以量化 AP 的活动。在修订后的亚特兰大分类严重程度和 LOS 组中,PASS 轨迹存在显著差异,这可用于 AP 的监测/管理(ClinicalTrials.gov 编号:NCT03075618)。